Variable CGRP family peptide signaling durations and the structural determinants thereof
- 24 April 2024
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 224, 116235
Abstract
No abstract availableKeywords
Funding Information
- Oklahoma Center for the Advancement of Science and Technology (HR23-002)
- National Institutes of Health
- National Institute of General Medical Sciences (R01GM104251)
This publication has 38 references indexed in Scilit:
- Adrenomedullin 2/intermedin is a slow off-rate, long-acting endogenous agonist of the adrenomedullin2 G protein–coupled receptorJournal of Biological Chemistry, 2023
- RAMPs as allosteric modulators of the calcitonin and calcitonin-like class B G protein-coupled receptors2020
- Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?Drug Discovery Today, 2016
- Adrenomedullin in lymphangiogenesis: from development to diseaseCellular and Molecular Life Sciences, 2015
- Low-dose adrenomedullin-2/intermedin(8–47) reduces pulmonary ischemia/reperfusion injuryPeptides, 2014
- Examining the binding properties of MK-0974: A CGRP receptor antagonist for the acute treatment of migraineEuropean Journal of Pharmacology, 2009
- Expression of adrenomedullin2/intermedin in human brain, heart, and kidneyPeptides, 2007
- Pharmacology of the human CGRP1 receptor in Cos 7 cellsPeptides, 2006
- Binding properties of the novel, non-peptide CGRP receptor antagonist radioligand, [3H]BIBN4096BSEuropean Journal of Pharmacology, 2002
- Differential expression of α-CGRP and β-CGRP by primary sensory neurons and enteric autonomic neurons of the ratNeuroscience, 1988